Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14689MR)

This product GTTS-WQ14689MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in B cell lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14689MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ59MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ9022MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ11660MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ6037MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ15735MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ7093MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ9294MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ13808MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-10933
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW